The Australian medicinal cannabis industry is experiencing a boom, with retail pharmacy sales reaching at least A$165 million in 2023, according to the latest data from research firm NostraData. This represents a 60% increase from 2022 and reflects the growing demand and acceptance of cannabis as a medicine. However, the market is also facing fierce competition from both local and international players, who are vying for a share of the lucrative sector.
NostraData reveals market insights
NostraData, a leading provider of data and analytics for the cannabis industry, has released its latest report on the Australian medicinal cannabis market, based on retail pharmacy sales data. The report shows that the industry is growing rapidly, with more than 100,000 patients accessing cannabis products in 2023, up from 65,000 in 2022. The average monthly spend per patient also increased from A$260 to A$280, indicating a higher consumption and willingness to pay.
The report also reveals the market share of the top 10 cannabis companies in Australia, based on retail pharmacy sales. The list is dominated by local firms, such as Little Green Pharma, MediPharm Labs, Althea, Cannatrek, and Creso Pharma, which collectively account for 65% of the market. However, the report also shows that the competition is intensifying, with new entrants and established players challenging the incumbents. For example, Tilray, a Canadian company that merged with Aphria in 2022, has increased its market share from 3% to 9% in 2023, becoming the second-largest cannabis company in Australia. Similarly, ECS Botanics, an Australian company that acquired Murray Meds in 2022, has grown its market share from 1% to 4% in 2023, ranking seventh in the list.
Industry consolidation is on the horizon
The NostraData report suggests that the Australian medicinal cannabis market is transforming as the industry matures and consolidates. The report states that the market is becoming more competitive, with more products, brands, and formats available to consumers. The report also predicts that the market will see more mergers and acquisitions, as well as strategic partnerships, shortly as companies seek to gain scale, efficiency, and differentiation.
Steve Jones, the co-founder and CEO of NostraData, said that the report provides valuable insights for industry stakeholders who need to adapt to the changing market dynamics. “2023 has been a challenging but progressive year for the Australian medicinal cannabis industry. We have seen explosive growth in patient numbers and sales but also increased competition and pressure on margins. The industry is evolving rapidly, and we expect to see more consolidation and innovation in the coming years,” Jones said.
The global outlook remains positive
The Australian medicinal cannabis market is not only influenced by domestic factors but also by global trends and developments. According to a recent report by Prohibition Partners, a global cannabis consultancy, the global recreational marijuana market is poised for explosive growth, with legal sales expected to nearly double to $50 billion by 2027. The report attributes this surge to two key factors: continued momentum in cannabis reform in the U.S. and new recreational cannabis markets emerging in Europe, which are creating fresh opportunities for the industry.
The report also highlights the regional differences and challenges in the global cannabis market. For example, North America remains the leader in the cannabis sector, with strong state-by-state growth in the U.S. and Canada’s established market. However, the U.S. market is still hampered by federal prohibition, which limits access to banking, taxation, and interstate commerce. On the other hand, Europe is becoming a new frontier for the cannabis industry, with countries such as Malta, Switzerland, the Netherlands, and Germany moving towards legalizing recreational cannabis. However, the European market is also fragmented and complex, with different regulatory frameworks and consumer preferences. Other regions, such as Latin America, Africa, Oceania, and Asia, are also showing signs of potential, with growing medical cannabis production and access, as well as increasing cannabis imports and exports.
Alex Khourdaji, a senior analyst at Prohibition Partners and co-author of the report, said that the global cannabis industry is facing both opportunities and challenges as the market expands and diversifies. “The global cannabis industry is at a pivotal point, with new markets opening up and existing markets maturing. The industry is becoming more competitive and sophisticated, with more products, brands, and formats available to consumers. However, the industry is also facing regulatory uncertainty, political resistance, and social stigma, which could hamper its growth potential,” Khourdaji said.